Norfloxacin use in urinary tract infection by urologists and infectious disease specialists

M. J. Kunkel; P. B. Iannini; R. Landes; L. Harrison; G. Wells; R. Snow; A. J. Schaeffer; E. J C Goldstein; S. Berman

doi:10.1159/000464088

Norfloxacin use in urinary tract infection by urologists and infectious disease specialists

M. J. Kunkel^*, P. B. Iannini, R. Landes, L. Harrison, G. Wells, R. Snow, A. J. Schaeffer, E. J C Goldstein, S. Berman

^*Corresponding author for this work

Urology

Research output: Contribution to journal › Article › peer-review

Abstract

One hundred thirty-one patients of urologists and infectious disease specialists were entered into an open trial of norfloxacin in the therapy of urinary tract infections (UTIs). All patients were evaluable for tolerability and 98 were evaluable for efficacy. The patient population in this study was older (mean age 53 years) and had more underlying urogenital disorders (30%) or recent invasive urologic procedures (20%) than the typical patient population with UTIs. Over 50% of the patients had infections due to organisms other than Escherichia coli, including Pseudomonas aeruginosa (14), Klebsiella pneumonia (5), Enterobacter spp (3) and Group D streptococcus (6). Clinical and bacteriologic cure rates were 90 and 91%, respectively. Side effects occurred in 5 patients and were generally mild.

Original language	English (US)
Pages (from-to)	30-33
Number of pages	4
Journal	European urology
Volume	17
Issue number	SUPPL. 1
DOIs	https://doi.org/10.1159/000464088
State	Published - 1990

Keywords

Norfloxacin
Quinolones
Urinary tract infection

ASJC Scopus subject areas

Urology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1159/000464088

Cite this

@article{6ed186b15fb040a8832475ecc2ac8915,

title = "Norfloxacin use in urinary tract infection by urologists and infectious disease specialists",

abstract = "One hundred thirty-one patients of urologists and infectious disease specialists were entered into an open trial of norfloxacin in the therapy of urinary tract infections (UTIs). All patients were evaluable for tolerability and 98 were evaluable for efficacy. The patient population in this study was older (mean age 53 years) and had more underlying urogenital disorders (30%) or recent invasive urologic procedures (20%) than the typical patient population with UTIs. Over 50% of the patients had infections due to organisms other than Escherichia coli, including Pseudomonas aeruginosa (14), Klebsiella pneumonia (5), Enterobacter spp (3) and Group D streptococcus (6). Clinical and bacteriologic cure rates were 90 and 91%, respectively. Side effects occurred in 5 patients and were generally mild.",

keywords = "Norfloxacin, Quinolones, Urinary tract infection",

author = "Kunkel, {M. J.} and Iannini, {P. B.} and R. Landes and L. Harrison and G. Wells and R. Snow and Schaeffer, {A. J.} and Goldstein, {E. J C} and S. Berman",

year = "1990",

doi = "10.1159/000464088",

language = "English (US)",

volume = "17",

pages = "30--33",

journal = "European urology",

issn = "0302-2838",

publisher = "Elsevier",

number = "SUPPL. 1",

}

TY - JOUR

T1 - Norfloxacin use in urinary tract infection by urologists and infectious disease specialists

AU - Kunkel, M. J.

AU - Iannini, P. B.

AU - Landes, R.

AU - Harrison, L.

AU - Wells, G.

AU - Snow, R.

AU - Schaeffer, A. J.

AU - Goldstein, E. J C

AU - Berman, S.

PY - 1990

Y1 - 1990

N2 - One hundred thirty-one patients of urologists and infectious disease specialists were entered into an open trial of norfloxacin in the therapy of urinary tract infections (UTIs). All patients were evaluable for tolerability and 98 were evaluable for efficacy. The patient population in this study was older (mean age 53 years) and had more underlying urogenital disorders (30%) or recent invasive urologic procedures (20%) than the typical patient population with UTIs. Over 50% of the patients had infections due to organisms other than Escherichia coli, including Pseudomonas aeruginosa (14), Klebsiella pneumonia (5), Enterobacter spp (3) and Group D streptococcus (6). Clinical and bacteriologic cure rates were 90 and 91%, respectively. Side effects occurred in 5 patients and were generally mild.

AB - One hundred thirty-one patients of urologists and infectious disease specialists were entered into an open trial of norfloxacin in the therapy of urinary tract infections (UTIs). All patients were evaluable for tolerability and 98 were evaluable for efficacy. The patient population in this study was older (mean age 53 years) and had more underlying urogenital disorders (30%) or recent invasive urologic procedures (20%) than the typical patient population with UTIs. Over 50% of the patients had infections due to organisms other than Escherichia coli, including Pseudomonas aeruginosa (14), Klebsiella pneumonia (5), Enterobacter spp (3) and Group D streptococcus (6). Clinical and bacteriologic cure rates were 90 and 91%, respectively. Side effects occurred in 5 patients and were generally mild.

KW - Norfloxacin

KW - Quinolones

KW - Urinary tract infection

UR - http://www.scopus.com/inward/record.url?scp=0025248889&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025248889&partnerID=8YFLogxK

U2 - 10.1159/000464088

DO - 10.1159/000464088

M3 - Article

C2 - 2354709

AN - SCOPUS:0025248889

SN - 0302-2838

VL - 17

SP - 30

EP - 33

JO - European urology

JF - European urology

IS - SUPPL. 1

ER -

Norfloxacin use in urinary tract infection by urologists and infectious disease specialists

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this